JANX
Janux Therapeutics Inc
NASDAQ: JANX · HEALTHCARE · BIOTECHNOLOGY
$14.18
-2.51% today
Updated 2026-05-08
Market cap
$891.26M
P/E ratio
—
P/S ratio
89.13x
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$12 – $35
Volume
1.0M
WallStSmart proprietary scores
40
out of 100
Grade: D
Sell
Investment rating
6.7
Growth
B8.5
Quality
A2.5
Profitability
F6.7
Valuation
B3/9
Piotroski F-Score
Weak
16.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →195 stocks currently score above 75
Price targets
Analyst target
$44.12
+211.25%
12-Month target
—
—
Intrinsic (DCF)
$38.74
Margin of safety
+66.16%
3 Strong Buy14 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 16.33 — safe zone
+ Revenue growth 2,178.00% QoQ
+ 66.16% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-28.65M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $8.61M | $8.08M | $10.59M | $10.00M | $10.00M |
| Net income | $-54.15M | $-58.29M | $-68.99M | $-113.63M | $-31.95M |
| EPS | — | — | — | — | $-1.83 |
| Free cash flow | $-49.37M | $-52.42M | $-44.17M | $-83.28M | $-28.65M |
| Profit margin | -628.82% | -721.18% | -651.62% | -1,136.25% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-02 | GO, WILLIAM | Buy | 154,000 | — |
| 2026-02-02 | GO, WILLIAM | Buy | 44,000 | — |
| 2026-01-02 | WINTER, CHARLES M. | Buy | 100,100 | — |
Peer comparison
Smart narrative
Janux Therapeutics Inc trades at $14.18. Our Smart Value Score of 40/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 16.33, it sits in the safe zone. TTM revenue stands at $10.00M. Our DCF model estimates intrinsic value at $38.74.
Frequently asked questions
What is Janux Therapeutics Inc's stock price?
Janux Therapeutics Inc (JANX) trades at $14.18.
Is Janux Therapeutics Inc overvalued?
Smart Value Score 40/100 (Grade D, Sell). DCF value $38.74.
What is the price target of Janux Therapeutics Inc (JANX)?
The analyst target price is $44.12, representing +211.3% upside from the current price of $14.18.
What is the intrinsic value of Janux Therapeutics Inc (JANX)?
Based on our DCF model, intrinsic value is $38.74, a +66.2% margin of safety versus $14.18.
What is Janux Therapeutics Inc's revenue?
TTM revenue is $10.00M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
16.33 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio89.13x
ROE-11.50%
Beta2.57
50D MA$14.34
200D MA$19.58
Shares out0.06B
Float0.04B
Short ratio—
Avg volume1.0M
Performance
1 week+1.39%
1 month+0.07%
3 months+11.25%
YTD+5.36%
1 year—
3 years—
5 years—